Our study identifies EZH2 as a potent inhibitor of antitumor immunity and responsiveness to CPI. This data suggests EZH2 inhibition as a novel therapeutic direction to enhance prostate cancer response to PD-1 CPI.
Main Text
Prostate cancer (PCa) is the currently the most commonly diagnosed non-cutaneous malignancy and the second most common cause of cancer death amongst men in the The enhancer of zeste homologue 2 (EZH2) is the methyltransferase catalytic subunit of the polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 of histone H3
(H3K27me3) to promote transcriptional repression (2) . Increased expression and activity of EZH2 is an important contributor to PCa initiation and progression (3, 4) . EZH2 can negatively regulate interferon (IFN) response genes, Th-1 type chemokines, and MHC expression in multiple tumor cell types (5, 6) . Dysfunction of epigenetic regulation within a cancer cell including effects mediated by EZH2, DNA methytransferases (DNMT), histone deacetylases (HDAC), BET bromodomains, and lysine specific demethylase 1 (LSD1) have proven to be critical mediators of acquired tumor immune escape.
Subsequent inhibition of these epigenetic mechanisms results in increased tumor immunity and successful combination with CPI in preclinical cancer models (5, (7) (8) (9) (10) (11) (12) (13) (14) .
Importantly, recent data from a phase Ib/II clinical trial, ENCORE-601 (NCT02437136), illustrated the power of epigenetic therapy to restore partial sensitivity in melanoma patients who had progressed on an inhibitor of PD-1 (15) . However, targeting epigenetic mechanisms, especially those mediated by EZH2, have not been tested for their ability to induce response to CPI in PCa.
Using 3-dimensional tumor organoids derived from a genetically engineered mouse model of PCa (GEMM) that expresses oncogenic cMYC, Ezh2 floxed alleles (16) , and an inducible Cre recombinase driven by the prostate specific antigen promoter (17) (EMC mouse, fig. S1 ), we demonstrated that chemical or genetic inhibition of EZH2 catalytic activity resulted in diminished organoid growth ( Fig. 1A and 1D ), accompanied by significant decrease in DNA synthesis and H3K27me3 ( Fig. 1B and 1E ). Independent gene set enrichment analysis (GSEA) revealed a significant enrichment of type I (IFN∝) and II (IFNγ) gene signatures ( Fig. 1G, fig. S1 ). The enrichment of IFN response genes following EZH2 inhibition had been previously demonstrated to be exclusive to cMYC over-expressing PCa models (14) . However, we didn't observe enrichment of IFN response genes exclusive to MYC over-expression in human datasets (data not shown).
Interrogation of the leading-edge genes related to IFN signaling from mouse PCa organoids revealed significant increases in expression of Th-1 chemokines (Cxcl9, Cxcl10, Cxcl11), antigen-presentation genes (B2m, Tap1), and IFNγ regulated genes These 3 proteins heterodimerize to form transcriptional machinery that drive IFN response gene expression (18) .
To determine if loss of EZH2 catalytic activity was associated with enrichment of IFN response genes in human PCa, a 29-gene EZH2 repression signature was derived using differentially expressed genes following chemical inhibition of EZH2 (Fig. 1C, table S3) and applied to independent human PCa RNAseq data sets (table S4) . A similar EZH2
repression signature was previously reported (19) S2 ). Upon quartile distribution of patients, differential gene expression between quartile 4 (lowest EZH2 activity) and quartile 1 (highest EZH2 activity) validated our in vitro murine results by indicating patients with lowest EZH2 activity were enriched for type I/II IFN response genes ( Fig. 1I, fig. S3 ). In line with our in vitro data, low EZH2 activity in PCa patients was also associated with increased expression of Th-1 chemokines (CXCL10, CXCL11), antigen-presentation (B2M, HLA-A), and IFNγ regulated genes (STAT1, IRF9) ( fig. S4 , table S1).
One potential mechanism underlying enrichment of IFN gene response to EZH2 inhibition would be upregulation of interferons themselves, however supernatants from murine PCa in vitro models following EZH2 inhibition were tested and showed no induction of soluble IFNα or IFNγ (data not shown). Recently, epigenetic targeted therapies were shown to induce IFN gene response by de-repression of double-strand RNA (dsRNA) (7, 9, 10) . This mechanism is known as viral mimicry and involves the reexpression of dormant transposable elements by treatment with epigenetic therapies (7, 9, 10) . This instructs the cancer cell to adapt and respond as if infected by an exogenous virus and mount an innate immune defense via induction of dsRNA sensor machinery and IFN response genes (20) . Indeed, treatment with EZH2 inhibitors significantly induced total intracellular levels of dsRNA in murine and human 3D PCa organoids ( We next overlaid both mouse and human IFNα/γ differentially expressed genes from figure 1J and 1I to identify an overall 97-gene IFN gene signature ( Fig. 2A and 2B ).
Importantly, cross-species analysis solidified the importance towards EZH2 regulation of TH1 chemokines (CXCL10, CXCL11), MHC class I pathway genes (B2M, TAP1), and IFN response genes (STAT1/2, IRF9, and CD274) in PCa ( Fig. 2B ). Collectively, there was an enrichment for biological and molecular gene ontology terms including innate immune response and double-stranded RNA binding and Tap binding ( fig. S7 ), validating our previous findings ( Fig. 1) . Because low EZH2 catalytic activity was associated with the upregulation of these genes, we proceeded to interrogate the chromatin landscape in primary PCa patient samples. Surprisingly, these 97 genes did not display overall enrichment for H3K27me3 or DNA methylation indicating that repression of these genes was not directly regulated by EZH2 or DNA methyltransferase activity. Instead, we observe that these genes are associated with enrichment of H3K27ac and open chromatin regions as assessed by ATAC-seq ( Fig. 2C, fig. S8 ). It was recently demonstrated that in high-grade gliomas driven by loss of H3K27me3 due to a H3K27M mutation that distinct areas of the genome become enriched for H3K27ac (22) . These enriched H3K27ac sites appeared at repeat elements resulting in their increased expression which was further amplified following treatment with DNA methyltransferase and HDAC inhibitors, suggesting these locations are primed for rapid activation (22) . Consistent with this, our 97-gene IFN signature was significantly up-regulated upon inhibition of EZH2 catalytic activity in PCa models ( Fig. 2D ).
Within our IFN gene signature, we further analyzed the regulation of CD274 (PD-L1) by EZH2 activity. Correlation analysis of patient PCa samples indicated that patients with lowest EZH2 activity had significant enrichment of PD-L1 gene expression ( Fig. 3A ).
Further, human prostatectomy samples with tumor PD-L1 protein overexpression (positivity in < 5% of tumor cells by immunohistochemistry) were stained for EZH2 protein, revealing opposing EZH2/PD-L1 expression patterns in the majority of tumors Strikingly, immune-mediated cytotoxicity was restored in EZH2 inhibitor treated cell lines by the addition of a PD-1 antibody, and this combination effect was also dependent on tumor PD-L1 upregulation (Fig. 3F ).
Based on the data, we proposed that EZH2 inhibition would sensitize PCa tumors in vivo to PD-1 CPI. Further support of this proposition was that human PCa samples with low EZH2 activity were significantly enriched for 2 gene signatures noted to predict response to checkpoint inhibition, a MImm-score (23) expression. This tumor response is associated with an overall increase of infiltrating CD3+, CD4+, CD8+ T-cells and M1 TAMs, and decreased M2 TAMs. The addition of PD-1 blockade to EZH2 inhibition executes the TME by further decrease of M2 TAMs and significant increase of activated CD8+ T-cells.
Materials and Methods

Experimental Models
Mouse Models
The Institute of Animal Care and Use Committee (IACUC) at Dana-Farber Cancer Institute approved all mouse procedures. C57BL/6N and FVB mice were obtained from Charles River Labs (Strain 027 and 207, respectively). Pten f/f ;Pb-Cre, Pb-HiMYC, Ezh2 fl/fl , and PSA-Cre(ERT2) strains have been described previously (17, 25, (33) (34) (35) (36) . All models were validated by genotyping PCR analysis prior to use in subsequent studies using genomic DNA extracted from mouse ears or tails. Genotyping primers used are detailed in Table S6 . The Ezh2 fl/fl ;Pb-HiMYC;PSA-Cre(ERT2) pos mice (EMC) mouse strain generated in this study were mixed background consisting of FVBN and C57Bl/6.
3D organoid models
All 3D organoid models were generated using previously described methodology and maintained in accordance as previously published (37) . Clinical samples were provided for organoid generation under IRB approval (Protocol Number: 17-571 -Ellis). Human 3D organoids were generated from 2 independent patient samples -a prostatectomy and a pleural effusion sample provided by Drs. Adam Kibel and Atish Choudhury respectively (IRB Protocol Number: 01-045 -Gelb Center DFCI/HCC). Murine EMC 3D organoids were generated from the dorsolateral prostates of 8-week-old GEMMs, whereas the Pten -/-3D organoids were generated from end-stage prostate tumors at 61 weeks-of-age.
Mouse 3D organoids were validated by genotyping and recombination PCRs prior to use in subsequent studies. All primers are detailed in Table S6 .
2D cell lines
Pten -/and B6MYC-CaP murine cell lines have been previously described and maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (Sigma) (25, 38) . The 
Therapy Experiments
In Vitro Assays For all in vitro therapy experiments, cells were seeded at the following concentrations:
2D cell lines were seeded at a concentration of 25,000 cells per well of a 24-well plate;
3D organoids were seeded at a concentration of 20,000 cells per 40 µL Matrigel disc (1 disc per well of a 24-well plate). In both cases, each well was treated with either 1 µM or 5µM DZNep or EPZ6438, or DMSO control, or 100U/mL interferon gamma control.
Mixed Lymphocytic Reaction Assay
Spleens from wildtype FVB mice were mashed through a sterile 40µm cell strainer (Corning) that had been pre-wet with sterile PBS (Gibco). Red blood cells were lysed using a commercial ACK Lysing Buffer (Gibco). The resulting splenocytes were frozen down at a concentration of 20x10 6 Table S5 ). Following antibody incubation, splenocytes derived from FVB mice were added at a tumor cell:splenocyte ratio of 1:10.
Cells were co-cultured with splenocytes for 8 hours, after which the plates were spun down and 50µL of supernatant was extracted for assessment of cytotoxicity. Cytotoxicity was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to manufactures instructions. Cytotoxicity was measured using a SpectraMax plate reader (Molecular Devices).
In Vivo Therapy Experiment
Pb-HiMyc derived tumor tissue (25) was sectioned in 2mm 2 tumor chunks and subcutaneously implanted into syngeneic C57BL/6N mice (Charles River Laboratories).
Four days following implant, mice were treated with either 250 mg/kg EPZ0011989 (Epizyme) or 0.5% CMC by oral gavage twice daily, 200µg anti-PD-1 (29F.1A12) or
IgG control (2A3) by intraperitoneal (IP) injection every 3 days started on the 5th day after initiation of EZH2i therapy, or combination (antibodies detailed in Table S5 ).
Tumor size was measured 3 times a week by caliper measurements. Mouse weights were monitored 3 times a week. Treatment toxicities will be assessed by body weight (twice weekly), decreased food consumption, signs of dehydration, hunching, ruffled fur appearance, inactivity or non-responsive behavior. Tumor tissue from each mouse was s were further assessed by flow cytometry, histopathology and immunohistochemical procedures.
Immunohistochemical and Immunofluorescent Staining and Quantification
In Vitro Samples Table S5 . Antibodies used are detailed in Table S5 . For analysis, 20 representative images from each tumor were taken using an EVOS FL Auto 2 Cell Imaging System. Staining intensity was scored using analysis pipelines generating in Image J software (40) (IHC staining) or CellProfiler software (41) (IF staining).
In Vivo Samples
Clinical Samples
The human prostatectomy tissue used have been previously described (42) , and was assessed as described by Calagua et al. Briefly, immunohistochemical staining was carried out on a Dako Link 48 autostainer. Sections were incubated with primary antibody for 1 hour, followed by amplification using Envision FLEX rabbit or mouse linkers, and visualization using the Envision Flex High-sensitivity visualization system (Dako). Tumor PD-L1 positivity was defined by moderate to strong membranous staining, and cytoplasmic staining was not considered. Scoring was performed semiquantitatively as follows: 0 (negative or < 1%), 1 (1%-4%), 2 (5%-24%), 3 (25%-49%), and 4 (≥ 50%). Antibodies are detailed in Table S5 .
Flow Cytometry
In vitro analysis
The Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay kit (ThermoFisher) was used to measure DNA synthesis according to manufacturer's instructions. Cultures were treated for 72 hours. Organoid discs were dislodged by pipetting, then digested to a single cell suspension by treatment with TrypLE (Gibco), which was in turn deactivated by resuspension in DMEM (Gibco) supplemented with 10% FBS (Sigma). Cells were washed with PBS (Gibco) by centrifugation at 500g at 4˚C and fixed with 4% paraformaldehyde for 15 minutes. Following another PBS wash, cells were permeabilized by the addition of ice-cold methanol to a final concentration of 90% methanol. This suspension was incubated for 30 minutes on ice. Following 2 washes with FACS buffer (PBS supplemented with 10% FBS), cells were resuspended in primary antibody prepared in FACS buffer (antibodies detailed in Table S5 ). These cell suspensions were incubated overnight in the dark at 4˚C or for 1 hour at room temperature. Cells were washed two additional times in FACS buffer. H3K27me3 and Edu was analyzed using an Amnis ImageStream Mark II (Luminex) and dsRNA and PD-L1 with a BD LSRFortessa (BD Biosciences).
In Vivo Tumor Analysis
Tumors were mechanically dissociated and filtered into single-cell suspensions in PBS on ice. Tumors were analyzed as follows. Cells were washed with PBS (Gibco) by centrifugation at 500g at 4˚C and fixed with 4% paraformaldehyde for 15 minutes.
Following another PBS wash, cells were permeabilized by the addition of ice-cold methanol to a final concentration of 90% methanol. This suspension was incubated for 30 minutes on ice. Following 2 washes with FACS buffer (PBS supplemented with 5% FBS), cells were resuspended in primary antibody prepared in FACS buffer. These cell suspensions were incubated overnight in the dark at 4˚C or for 1 hour at room temperature. Cells were washed two additional times in FACS buffer and analyzed as on a BD LSRFortessa (BD Biosciences, Dana-Farber Cancer Institute), separated into "CD45-" and "CD45+" events. Antibodies used are detailed in Table S5 .
In Vivo Tumor Immune Profiling
Tumor cell suspensions were stained using two different antibody panels: lymphocytes or myeloid, using appropriate IgG and full minus one (FMO) controls, followed by analysis Table S5 .
Quantitative Real Time PCR
Quantitative PCRs were performed in accordance with MIQE guidelines (43) . RNA was harvested using a standard TRIzol ® protocol according to manufacturer's instructions.
cDNA was synthesized using the qScript cDNA SuperMix (Quantabio) according to manufacturers' instructions. The SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) was used for PCRs using the cycling conditions recommended in the manufacturers'
instructions. Primers used are detailed in Table S6 .
Statistical Methods
Graph preparation and statistical analyses of in vitro and in vivo experiments was performed with the GraphPad Prism software. Statistical significance for assays was assessed using a Welch's corrected un-paired t-test unless otherwise stated. Specific for in vivo tumor growth curves (fig. 4B ), a multiple t-test was used to assess therapy
response. An observation with a p-value of <0.05 was considered statistically significant. (45) .
Sequencing Analysis
RNA Sequencing Data Generation
Additional Datasets Used
Microarray data for LNCaP cell lines treated with EZH2 inhibitor has been previously described (46 
Molecular Signatures
The HALLMARK_INTEFERON_GAMMA_RESPONSE and HALLMARK_INTERFERON_ALPHA_RESPONSE molecular genesets were obtained from the Molecular Signatures Database (MSigDB v6.2). A complete, and refined polycomb repression signature has also been previously described (19) . Molecular signatures used to define the immune microenvironment included the Ayers et al.
preliminary expanded immune signature (24) , and the MImmScore (23).
Hallmark Interferon Leading Edge Gene List
DE analysis, and GSEA were performed on the 5 datasets indicated. A Hallmark Interferon Leading Edge Gene list was obtained for each dataset by taking the union of the leading edge genes identified in the GSEA reports for the HALLMARK_INTERFERON_GAMMA_RESPONSE and HALLMARK_INTERFERON_ALPHA_RESPONSE gene sets. An overall list of Hallmark Interferon leading edge genes was by genes that appeared in at least 3 out of 5 datasets.
ChIP Sequencing and ATAC Sequencing
Fresh-frozen radical prostatectomy specimens from patients with localized prostate cancer were obtained from the Dana-Farber Cancer Institute Gelb Center biobank under Dana-Farber Cancer Institute/Harvard Cancer Center IRB-approved protocols (Protocol Numbers: 01-045, 09-171). Hematoxylin and eosin (H & E) stained slides from each case were reviewed by a genitourinary pathologist. Areas estimated to be enriched >70% for prostate tumor tissue were isolated for analysis. ChIP-seq was performed using the protocol previously described (51) with antibodies to H3K27Ac (C15410196, Diagenode) and H3K27me3 (9733S, Cell Signaling Technology). Libraries were sequenced using 75 base pair reads on the Illumina platform. The ATAC-seq assay was performed at Active Motif using fresh-frozen Gelb Center RP tumor and normal epithelium specimens. The tissue was manually disassociated, isolated nuclei were quantified using a hemocytometer, and 100,000 nuclei were tagmented as previously described (52) , with some modifications (53) using the enzyme and buffer provided in the Nextera Library Prep Kit (Illumina). Tagmented DNA was then purified using the MinElute PCR purification kit (Qiagen), amplified with 10 cycles of PCR, and purified using Agencourt AMPure SPRI beads (Beckman Coulter). All samples were processed through the computational pipeline developed at the DFCI Center for Functional Cancer Epigenetics (CFCE) using primarily open source programs. Sequence tags were aligned with Burrows-Wheeler Aligner (BWA) to build hg19 of the human genome, and uniquely mapped, non-redundant reads were retained (54) . These reads were used to generate binding sites with Model-Based Analysis of ChIP-seq 2 (MACS v2.1.1.20160309), with a q-value (FDR) threshold of 0.01 (55) . The ChIP-Seq and ATAC-seq data will be reported separately (Pomerantz et al., submitted) . Bisulfite sequencing data from localized prostate tumors were reported previously (56) and processed and as previously described. deepTools (57) was used to create heatmaps for epigenomic data visualization.
